

- **Name:** Chang Gon Kim
 - **Current Position & Affiliation:** Clinical Assistant Professor, Yonsei Cancer Center
 - **Country:** Korea
-

- **Educational Background:**

2005-2011 Yonsei University College of Medicine, M.D.

2013-2015 Yonsei University College of Medicine, M.S.

2016-2020 Korea Advanced Institute of Science and Technology, Ph.D.

- **Professional Experience:**

2011-2016 Yonsei University Health System, Intern, Resident

2020-current Yonsei Cancer Center, Fellow, Clinical Assistant Professor

- **Professional Organizations:**

KSMO, ASCO, ESMO

- **Main Scientific Publications:**

A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*. 2024 May 15;30(10):2097-2110.

Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response. *Cell Reports Medicine*. 2023 Nov 21;4(11):101251.

Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2–positive advanced gastric or gastroesophageal junction cancer. *Journal of Clinical Oncology*. 2023 Sep 20;41(27):4394-4405.

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. *Journal of the American Academy of Dermatology*. 2022 Nov;87(5):989-996.

Phase II clinical trial of eribulin-gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma. *Clinical Cancer Research*. 2022 Aug 2;28(15):3225-3234.

Distinct exhaustion features of T lymphocytes shape the tumor-immune

microenvironment with therapeutic implication in patients with non-small-cell lung cancer. *Journal for ImmunoTherapy of Cancer*. 2021 Dec;9(12):e002780.

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. *Journal of Hepatology*. 2021 Feb;74(2):350-359.

VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. *Science Immunology*. 2019 Nov 8;4(41).

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. *Annals of Oncology*. 2019 Jul 1;30(7):1104-1113.